Heart failure and sudden death

Yong-Mei Cha, Win Kuang Shen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 % 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40-50 % were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 % in the period from 1950 to 1969 to 59 % in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 %. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease pathophysiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe. The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.

Original languageEnglish (US)
Title of host publicationElectrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition
PublisherSpringer-Verlag London Ltd
Pages395-412
Number of pages18
ISBN (Print)9781447149781, 9781447149774
DOIs
StatePublished - Jan 1 2013

Fingerprint

Sudden Death
Heart Failure
Mortality
Cardiac Arrhythmias
Heart Diseases
Homeostasis
Survival Rate
Clinical Trials
Equipment and Supplies
Survival

Keywords

  • Arrhythmia
  • Heart failure
  • Sudden death
  • Ventricular tachycardia
  • Ventricularfibrillation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cha, Y-M., & Shen, W. K. (2013). Heart failure and sudden death. In Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition (pp. 395-412). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4978-1_25

Heart failure and sudden death. / Cha, Yong-Mei; Shen, Win Kuang.

Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, 2013. p. 395-412.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cha, Y-M & Shen, WK 2013, Heart failure and sudden death. in Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, pp. 395-412. https://doi.org/10.1007/978-1-4471-4978-1_25
Cha Y-M, Shen WK. Heart failure and sudden death. In Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd. 2013. p. 395-412 https://doi.org/10.1007/978-1-4471-4978-1_25
Cha, Yong-Mei ; Shen, Win Kuang. / Heart failure and sudden death. Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition. Springer-Verlag London Ltd, 2013. pp. 395-412
@inbook{73342e2b6f1442f981da27127513979d,
title = "Heart failure and sudden death",
abstract = "Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 {\%} 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40-50 {\%} were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 {\%} in the period from 1950 to 1969 to 59 {\%} in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 {\%}. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease pathophysiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe. The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.",
keywords = "Arrhythmia, Heart failure, Sudden death, Ventricular tachycardia, Ventricularfibrillation",
author = "Yong-Mei Cha and Shen, {Win Kuang}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4978-1_25",
language = "English (US)",
isbn = "9781447149781",
pages = "395--412",
booktitle = "Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Heart failure and sudden death

AU - Cha, Yong-Mei

AU - Shen, Win Kuang

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 % 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40-50 % were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 % in the period from 1950 to 1969 to 59 % in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 %. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease pathophysiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe. The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.

AB - Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 % 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40-50 % were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 % in the period from 1950 to 1969 to 59 % in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 %. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease pathophysiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe. The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.

KW - Arrhythmia

KW - Heart failure

KW - Sudden death

KW - Ventricular tachycardia

KW - Ventricularfibrillation

UR - http://www.scopus.com/inward/record.url?scp=84949423317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949423317&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4978-1_25

DO - 10.1007/978-1-4471-4978-1_25

M3 - Chapter

AN - SCOPUS:84949423317

SN - 9781447149781

SN - 9781447149774

SP - 395

EP - 412

BT - Electrical Diseases of the Heart: Volume 2: Diagnosis and Treatment, Second Edition

PB - Springer-Verlag London Ltd

ER -